Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma

[1]  P. Singh,et al.  Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment , 2022, Journal of family medicine and primary care.

[2]  M. Kersten,et al.  Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 , 2022, Blood Cancer Journal.

[3]  R. Advani,et al.  Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. , 2022, Oncology.

[4]  G. Lenz,et al.  Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma , 2022, Therapeutic advances in hematology.

[5]  R. Schmitz,et al.  Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice , 2022, Current Oncology Reports.

[6]  T. Wilson,et al.  FCRL1 Regulates B Cell Receptor-Induced ERK Activation through GRB2. , 2021, Journal of Immunology.

[7]  S. Barta,et al.  2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management , 2021, American journal of hematology.

[8]  K. Young,et al.  New agents and regimens for diffuse large B cell lymphoma , 2020, Journal of Hematology & Oncology.

[9]  A. Inamdar,et al.  Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine , 2020, Oncotarget.

[10]  M. Othus,et al.  Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab? , 2020, Cancer medicine.

[11]  R. McCord,et al.  Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies , 2020, Translational Medicine Communications.

[12]  Pio Zeppa,et al.  Non-Hodgkin Lymphoma. , 2020, Monographs in clinical cytology.

[13]  Z. Yousefi,et al.  Prognostic significance of Fc receptor-like 1 in patients with chronic lymphocytic leukemia, hairy cell leukemia, and various B-cell non-Hodgkin's lymphoma , 2019, Leukemia research reports.

[14]  Quanzhen Li,et al.  Fc receptor–like 1 intrinsically recruits c-Abl to enhance B cell activation and function , 2019, Science Advances.

[15]  E. Campo,et al.  Aggressive B-cell lymphomas—from morphology to molecular pathogenesis , 2019, Annals of Lymphoma.

[16]  S. Sharifzadeh,et al.  Fc Receptor-Like 1 as a Promising Target for Immunotherapeutic Interventions of B-Cell-Related Disorders , 2019, Biomarker insights.

[17]  D. Hodson,et al.  Non-Hodgkin lymphoma , 2018, British Medical Journal.

[18]  M. Shabani,et al.  Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseases , 2018, Expert opinion on therapeutic targets.

[19]  K. Dybkær,et al.  AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. , 2017, The American journal of pathology.

[20]  A. Lagoo,et al.  Improved detection of diffuse large B‐cell lymphoma by flow cytometric immunophenotyping—Effect of tissue disaggregation method , 2016, Cytometry. Part B, Clinical cytometry.

[21]  A. Haque,et al.  Fc Receptor-Like Proteins in Pathophysiology of B-cell Disorder , 2016, Journal of clinical & cellular immunology.

[22]  Peter D. Crompton,et al.  Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function , 2015, eLife.

[23]  M. Dabbaghmanesh,et al.  Expression Profile of Human Fc Receptor-Like 1, 2, and 4 Molecules in Peripheral Blood Mononuclear Cells of Patients with Hashimoto’s Thyroiditis and Graves’ Disease , 2015, Hormone and Metabolic Research.

[24]  The.  Correction: Cross-Talk between NFkB and the PI3-Kinase/AKT Pathway Can Be Targeted in Primary Effusion Lymphoma (PEL) Cell Lines for Efficient Apoptosis , 2014, PLoS ONE.

[25]  L. Yeo,et al.  Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[26]  S. Pileri,et al.  IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas , 2012, Histopathology.

[27]  Xue Zhu,et al.  Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection , 2012, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[28]  A. Najakshin,et al.  Expression of human B-Cell specific receptor FCRL1 in healthy individuals and in patients with autoimmune diseases , 2012, Molecular Biology.

[29]  G. Lenz,et al.  The molecular biology of diffuse large B-cell lymphoma , 2011, Therapeutic advances in hematology.

[30]  J. Schatz.  Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies , 2011, Current oncology reports.

[31]  M. Zafarullah,et al.  High-efficiency transfection of nucleic acids by the modified calcium phosphate precipitation method in chondrocytes. , 2008, Analytical biochemistry.

[32]  N. Chiorazzi,et al.  FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. , 2008, Blood.

[33]  L. Staudt,et al.  Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. , 2008, Blood.

[34]  V. Canzonieri,et al.  Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-κB pathway as a target for new therapeutic strategies , 2008, Leukemia & lymphoma.

[35]  I. Pastan,et al.  FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. , 2007, Blood.

[36]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[37]  R. Davis.  Fc receptor-like molecules. , 2007, Annual review of immunology.

[38]  A. Ebens,et al.  Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. , 2006, International immunology.

[39]  Y. Natkunam,et al.  Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells , 2004, British journal of haematology.

[40]  M. Cooper,et al.  FcRH1: an activation coreceptor on human B cells. , 2004, Blood.

[41]  M. Cooper,et al.  Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family , 2002, Immunological reviews.

[42]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[43]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[44]  Randall S. Davis,et al.  Identification of a family of Fc receptor homologs with preferential B cell expression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  N. Palanisamy,et al.  IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. , 2001, Immunity.

[46]  W. Wilson,et al.  Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma , 2007, Leukemia.

[47]  M. Cooper,et al.  Fc receptor-like proteins (FCRL): immunomodulators of B cell function. , 2007, Advances in experimental medicine and biology.

[48]  L. Staudt,et al.  Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  L. Staudt,et al.  Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .

[50]  M. Cooper,et al.  FcRH 1 : an activation coreceptor on human B cells , 2004 .